Introduction {#S1}
============

Acquisition of genetic material including virulence, fitness and antibiotic resistance genes by horizontal gene transfer (HGT) is an essential process in bacterial adaptation to different environments ([@B11]). In addition bacteria have acquired an adaptive immune system, clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR-Cas), which helps to limit the acquisition of genetic materials and defend against invasive bacteriophages and plasmids ([@B13]; [@B3]; [@B37]).

A typical CRISPR-Cas locus is comprised of a CRISPR array, Cas genes and a leader sequence. A CRISPR array is comprised of nearly identical short (21 to 47 nucleotides) direct repeats, separated by unique DNA fragments (spacers) acquired from foreign DNA \[mobile genetic elements (MGEs)\]. The leader sequence is usually a (∼100--500 bp) AT rich region believed to serve as a promoter for the transcription of the CRISPR array ([@B26]). The CRISPR-Cas defense mechanism can be considered as three steps. In an initial adaptation step foreign DNA fragments (protospacers) from infecting bacteriophages and plasmids are incorporated into the CRISPR array as new spacers. These spacers provide the sequence specific memory for a targeted defense against subsequent invasions by the same bacteriophage or plasmid. The CRISPR array transcript is then processed to matured CRISPR RNAs (crRNAs). After expression of the array, mature crRNAs, aided by Cas proteins, identify specific targets and cleave the nucleic acid strands of corresponding viruses or plasmids ([@B42]; [@B13]; [@B23], [@B24]; [@B3]).

CRISPR-Cas systems show a great deal of diversity in their Cas protein composition, structure of effector proteins complex, genetic organization and localization in the genome, mechanism of adaptation, crRNA processing and interference. Based on the effector complexes CRISPR-Cas systems can be divided into two classes and six types (Class 1, including types I, III, IV and class 2, including types II, V and VI), those can be sub-divided into at least 34 sub-types ([@B23], [@B24], [@B25]; [@B20]; [@B17]), Class 1 CRISPR-Cas system provides interference by using multi-Cas effector protein complex whereas Class 2 uses single effector protein for interference ([@B17]). Generally there are signature genes for each type of CRISPR-Cas system and those include *cas3* for type I, *cas9* for type II, *cas10* for type III, *csf1* (large subunit, *cas8-*like) for type IV, *cas12* for type V, and *cas13* for type VI ([@B25]). Types I and II CRISPR-Cas systems provide immunity against DNA ([@B4]; [@B14]) whereas type III systems may target DNA or RNA ([@B41]). Types I--III are well-studied and are generally found in chromosomes of bacteria and archaea, whereas types IV, V, and VI are three putative new types. Type IV systems are usually localized on plasmids or other MGEs and lack apparent adaptation modules (*cas1* and *cas2*) and type V was identified in archaeal chromosome only ([@B22], [@B24]). Type VI is another new type identified recently carrying HEPN-domain containing effector protein Cas13, which, unlike, other class II effector cleaves single stranded RNA (ssRNA) ([@B17]). HEPN RNase is a toxin domain of bacterial toxin-antitoxin module and suggests that type VI includes dedicated RNA-targeting CRISPR-Cas system ([@B23], [@B25]; [@B20]).

The classification, functions and mechanism of actions of all CRISPR-Cas systems are well-characterized except type IV. A recent study demonstrated that the function of type IV system in the maturation of crRNAs and in the subsequent formation of a Cascade-like crRNA-guided effector complex ([@B32]). Type IV system can be classified as two sub-types, type IV-A and IV-B, based on the presence of DinG family helicase and type IV specific effector protein Csf5. Type IV-A encodes a DinG helicase (Csf4) and an effector protein Csf5 and whereas type IV-B lacks these proteins ([@B24], [@B25]; [@B20]; [@B17]; [@B34]) and usually, the type IV-A system carries CRISPR-array.

*Klebsiella pneumoniae*, a member of the bacterial family Enterobacteriaceae, is a common opportunistic hospital associated pathogen, accounting for about one third of total Gram-negative infections ([@B28]). It causes a variety of infections including urinary tract infections, pneumonia, cystitis, wound infections, and life-threatening sepsis ([@B35]). Occurrence of transmissible antibiotic resistance in this organism is a major problem worldwide. *K. pneumoniae* have a huge pool of antibiotic resistance genes that they share among other Enterobacteriaceae, mostly via self-transferrable plasmids ([@B28]). Almost all modern antibiotic resistance (to carbapenems, cephalosporins, aminoglycosides, now even colistin) in these organisms is encoded on large (40--200 kb) low-copy (1--6 per cell) conjugative plasmids ([@B5]; [@B28]). Plasmid-borne antibiotic resistance is acquired very quickly and, once acquired, could become fixed in the bacterial accessory genome by 'addiction systems' that poison cells from which the antibiotic resistance plasmid is lost ([@B16]).

Several studies have identified CRISPR-Cas systems in *K. pneumoniae* chromosomes as I-E and I-E^∗^ types ([@B31]; [@B40]; [@B21]) but little is known about CRISPR-Cas systems of plasmids in *K. pneumoniae* and other Enterobacteriaceae ([@B9]). CRISPR-Cas systems are associated with relative antibiotic susceptibility in *Streptococcus pyogenes* and *E. coli* and the chromosomal CRISPR-Cas system is known to interfere with acquisition of antibiotic-resistant plasmids in *E. coli* ([@B46]; [@B2]). In this study, we examined 699 complete plasmid sequences from *K. pneumoniae* and 217 *K. pneumoniae* chromosomal sequences from the GenBank for the presence of CRISPR-Cas system and further analyzed the identified CRISPR-Cas systems and their spacers.

Materials and Methods {#S2}
=====================

Extraction of Complete Nucleotide Sequence of Plasmids and Chromosomes for *K. pneumoniae* From the GenBank {#S2.SS1}
-----------------------------------------------------------------------------------------------------------

*Klebsiella pneumoniae* chromosome and plasmid sequences available in the GenBank database^[1](#footnote1){ref-type="fn"}^ were downloaded and subjected to CRISPR analysis. For complete *K. pneumoniae* chromosomal sequences, after opening the database link, we selected "genome assembly and annotation report" and chose complete sequences and then extracted all the complete nucleotide sequences individually and saved as FASTA format sequence file. For complete plasmid sequences, in the same link we selected "plasmid annotation report" and downloaded plasmid sequences \> 50 kb and saved as separate FASTA files for individual plasmid sequences.

Identification and Characterization of CRISPR-Cas in Plasmid and Chromosomal Sequences {#S2.SS2}
--------------------------------------------------------------------------------------

CRISPR was identified with CRISPRFinder^[2](#footnote2){ref-type="fn"}^ ([@B15]) software. This algorithm locates direct repeat sequences of 23--55 bp separated by variable sequences of a size no greater than 2.5 times or no less than 0.6 times the length of the repeated sequences (25--60 bp). When the algorithm detects at least three repeating regions that are exactly the same (in sequence and size), which are separated by variable sequences, it is considered a "confirmed CRISPR." If the algorithm locates two repeats separated by a variable sequence, it establishes the status of a "questionable CRISPR." For the present study we only considered those indicated by the program as "confirmed CRISPRs." In addition, with this platform, we searched for *cas* genes in regions adjacent to CRISPR sequences. Fasta formatted complete nucleotide sequence of each individual plasmid or chromosome was uploaded in the CRISPRFinder and run the program by using a default setting parameters and outcomes provided the possible CRISPR-array (CRISPR repeats and spacers). Spacers sequences were collected from CRISPRFinder outputs and saved to use for further analysis. The CRISPR region identified by CRISPRFinder was then detected on the plasmid or chromosomal sequences and nearly 10 kb upstream and downstream regions were analyzed for putative *cas* genes. The CRISPR-array neighboring genes and their respective protein sequences were analyzed by BLASTn and BLASTp searches for the GenBank identity. For nucleotide sequence analysis, megablast was performed by using following parameters: (i) expectation threshold (e-values) less than or equal to 0.01 and a score greater than 40, (ii) maximum target sequence was set at 1000, (iii) automatically adjusted parameters for short input sequences, (iv) different match/mismatch scores were selected to identify highly conserved to low conserved sequences. BLASTp for protein sequences were performed against non-redundant protein sequence database and against reference proteins sequence database with expectation values (e-value) less than or equal to 0.01 were considered significant as well as a coverage percentage of more than or equal to 80%. The identified CRISPR-array and *cas* genes were further verified by using CRISPRone software^[3](#footnote3){ref-type="fn"}^ ([@B45]). The individual fasta formatted nucleotide sequence of plasmid and chromosome was run through CRISPRone software by using default settings.

Search for Similar CRISPR-Cas System in GenBank Data {#S2.SS3}
----------------------------------------------------

The *cas* genes identified in the putative type IV CRISPR-Cas systems in the plasmids of *K. pneumoniae* were used to fish similar type of CRISPR-Cas system in the GenBank data. Both the *cas* genes nucleotide sequences and amino acid sequences were used separately for BLASTn and BLASTp search in the GenBank data with the parameters mentioned earlier. The additional plasmid sequences identified with identical *cas* genes or Cas proteins were downloaded and analyzed for CRISPR-array and *cas* genes orientation by CRISPRFinder and CRISPRone software.

Analysis of CRISPR Spacers and Identification of Spacers Protospacers Match {#S2.SS4}
---------------------------------------------------------------------------

Spacers from respected plasmid CRISPR-Cas system were extracted from CRISPRFinder outputs and made a fasta formatted sequence file for all spacer pool by BioEdit software^[4](#footnote4){ref-type="fn"}^. Each of the spacers sequence, their reverse complement sequence and both 3′ and 5′ truncated version were then searched against the spacer pool and identified all the unique spacers found in the plasmid CRISPRs and then plotted their distribution. Each of the unique spacer was then analyzed for their identity (match with protospacers) to GenBank sequences by nucleotide blast search (BLASTn) with parameters described earlier.

Identification of Chromosomal CRISPR Type {#S2.SS5}
-----------------------------------------

Two different types of *cas1* and *cas3* alleles were found in *K. pneumoniae* genomes and CRISPR-Cas systems were further divided into types I-E or I-E^∗^ ([@B21]) on the basis of the *cas1* and *cas3* alleles and their localization in the chromosome.

Plasmid Characterization {#S2.SS6}
------------------------

The presence of antibiotic resistance genes in sequenced plasmids were identified by ResFinder 3.2^[5](#footnote5){ref-type="fn"}^ and plasmid replicon types by PlasmidFinder 2.1^[6](#footnote6){ref-type="fn"}^ ([@B7]).

Results {#S3}
=======

CRISPR-Cas System in *K. pneumoniae* Plasmids {#S3.SS1}
---------------------------------------------

A total of 699 complete plasmid sequences of \> 50-kb in size found in *K. pneumoniae* were extracted from the GenBank database. CRISPR-arrays were identified in 5% (37 of 699; [Table 1](#T1){ref-type="table"} and [Supplementary Table S1](#DS1){ref-type="supplementary-material"}) of the plasmids. The identified CRIPSR-arrays had direct repeats of 23--30 bp separated by a variable number (0--22) of spacer sequences of 25--57 bp and most of them are 30--33 bp long ([Supplementary Table S2](#DS1){ref-type="supplementary-material"}). Immediately upstream of the CRISPR-array an ∼130 bp conserved AT rich region was present, which may act as a leader sequence of this CRISPR. We also identified *csf2*, *csf3*, *DinG helicase (csf4)*, *cas6* (*csf5*), *csx3*, and *cas10* homologs upstream and a reverse transcriptase (*RTase*) or maturase gene downstream of the CRISPR-array ([Figure 1](#F1){ref-type="fig"}). Two genes of unknown function were also present in the *Cas* genes locus, but we could not identify the adaptation genes *cas1* or *cas2*, or evident homologs, in these plasmids. The structure of the CRISPR-Cas array and organization of *cas* genes identified here is very close to that of the type IV CRISPR-Cas system previously identified in the mega-plasmid of *Aromatoleum aromaticum* EbN1, an aromatic-degrading betaproteobacteria found in freshwater and soil habitats ([@B32]), even though a large subunit (Csf1) that acts as the signature protein for this type ([@B24]) is absent from the system identified here. The *Cas* genes and their orientations in identified CRISPR-Cas systems are very similar among the plasmids except for the presence of Insertion Sequences (ISs) insertion events in some. ISs were also identified between the CRISPR-array and *RTase* gene in a few plasmids.

###### 

Characteristics of CRISPR-Cas positive plasmids.

  **Sl no.**   **Plasmid**                                        **Species^a^**   **Accession no.**          **CRISPR-array position**   **DR-length (bp)**   **No. of spacers**   **Plasmid size (kb)**   **Replicon type^b^**            **Antibiotic resistance genes identified (annotation by ResFinder^c^)**
  ------------ -------------------------------------------------- ---------------- -------------------------- --------------------------- -------------------- -------------------- ----------------------- ------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1            pKPM501                                            *Kp*             [CP031735.1](CP031735.1)   200609--201185              28                   9                    253                     IncFIB~*k*~, IncFII~*k*~        *bla*~*CTX--M--*15~, *bla*~*TEM--*1*A*~, *aac(6′)-Ib, aac(6′)-Ib-cr, dfrA14*
  2            unnamed_1                                          *Kp*             [CP022612.1](CP022612.1)   313185--313943              29                   12                   335                     IncHI1, IncHI1B, IncFIB, IncR   *bla*~*NDM--*1~, *bla*~*CTX--M--*15~, *bla*~*TEM--*1*A*~, *bla*~*OXA--*9~, *bla*~*SHV--*13~, *aph(3′)-VI, armA, aadA2, aadA1, aac(6′)-Ib, aac(6′)-Ib-cr, aac(3)-IId, aph(6)-Id, sul1,2,3; dfrA12*
  3            AR_0153 plasmid unnamed1                           *Kp*             [CP028929.1](CP028929.1)   62241--63001                29                   12                   283                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*OXA--*1~, *aph(3′)-VI, armA, aadA2, aac(6′)-Ib-cr, qnrB1, sul1, dfrA12, dfrA14*
  4            pKPN528-1                                          *Kp*             [CP020854.1](CP020854.1)   251737--252495              29                   12                   292                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*OXA--*1~, *aph(3′)-VI, armA, aadA2, aac(6′)-Ib-cr, qnrB1, sul1, dfrA12, dfrA14*
  5            AR_0068 plasmid unitig_1                           *Kp*             [CP020068.1](CP020068.1)   136244--137004              29                   12                   276                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*SHV--*13~, *aph(3′)-VI, armA, aadA2, aac(3)-IId, aph(6)-Id, sul1,2; dfrA12*
  6            pIncHI1B_DHQP1300920                               *Kp*             [CP016921.1](CP016921.1)   229597--230357              29                   12                   283                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*OXA--*1~, *aph(3′)-VI, armA, aadA2, aac(6′)-Ib-cr, qnrB1, sul1, dfrA12, dfrA14*
  7            KP617 plasmid KP-plasmid1                          *Kp*             [CP012754.1](CP012754.1)   114404--115164              29                   12                   273                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *aph(3′)-VI, armA, aadA2, qnrB1, sul1, dfrA12*
  8            PittNDM01 plasmid1                                 *Kp*             [CP006799.1](CP006799.1)   114132--114892              29                   12                   283                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*OXA--*1~, *aph(3′)-VI, armA, aadA2, aac(6′)-Ib-cr, qnrB1, sul1, dfrA12, dfrA14*
  9            pKJNM10C3.2                                        *Kp*             [CP030878.1](CP030878.1)   136256--137016              29                   12                   276                     IncHI1B, IncFIB                 *bla*~*NDM--*7~, *aph(3′)-VI, armA, aadA2, aph(3′′)-Ib, aph(6)-Id, aac(3)-IIa, sul1, 2; dfrA12*
  10           p18ES-342                                          *Kp*             [CM008881](CM008881)       52979--53610                23                   10                   332                     IncHI1B, IncFIB                 *dfrA1*
  11           unnamed1                                           *Kp*             [CP031818](CP031818)       223392--224022              23                   10                   430                     IncFIB                          None
  12           pKpvST147L                                         *Kp*             [CM007852](CM007852)       167552--168555              29                   16                   343                     IncHI1B, IncFIB                 *armA, aph(3′)-Ia, sul1, 2; dfrA5*
  13           KSB2_1B plasmid unnamed1                           *Kp*             [CP024507.1](CP024507.1)   41987--42747                29                   12                   310                     IncFIB                          None
  14           pKp_Goe_414-1                                      *Kp*             [CP018339.1](CP018339.1)   75291--76111                29                   13                   204                     IncFIB                          None
  15           pKPN-3967                                          *Kp*             [CP026186.1](CP026186.1)   221215--221302              27                   1                    373                     IncFIB                          None
  16           p44-1                                              *Kp*             [CP025462.1](CP025462.1)   42604--43120                29                   8                    261                     IncFIB                          None
  17           TVGHCRE225 plasmid unnamed1                        *Kp*             [CP023723.1](CP023723.1)   10881--11763                29                   14                   297                     IncHI1B, IncFIB                 None
  18           pOXA1_020030                                       *Kp*             [CP028791.1](CP028791.1)   30205--30843                29                   10                   288                     IncFIB                          *bla*~*OXA--*1~, *aac(6′)-Ib-cr, sul1*
  19           825795-1 plasmid unnamed1                          *Kp*             [CP017986.1](CP017986.1)   148524--149585              30                   17                   244                     IncHI1B, IncFIB                 None
  20           pKp_Goe_304-1                                      *Kp*             [CP018720.1](CP018720.1)   24563--25679                24                   18                   246                     IncHI1B, IncFIB                 None
  21           pKp_Goe_021-1                                      *Kp*             [CP018714.1](CP018714.1)   7697--8748                  30                   17                   246                     IncHI1B, IncFIB                 None
  22           pKp_Goe_026-1                                      *Kp*             [CP018708.1](CP018708.1)   54661--55777                24                   18                   246                     IncHI1B, IncFIB                 None
  23           pKp_Goe_024-1                                      *Kp*             [CP018702.1](CP018702.1)   5006--6122                  24                   18                   246                     IncHI1B, IncFIB                 None
  24           pKp_Goe_832-1                                      *Kp*             [CP018696.1](CP018696.1)   102143--103259              24                   18                   246                     IncHI1B, IncFIB                 None
  25           pKp_Goe_473-1                                      *Kp*             [CP018687.1](CP018687.1)   116666--117727              30                   17                   246                     IncHI1B, IncFIB                 None
  26           pKp_Goe_579-1                                      *Kp*             [CP018313.1](CP018313.1)   94773--95834                30                   17                   246                     IncHI1B, IncFIB                 None
  27           AR_0363 plasmid unnamed4                           *Kp*             [CP027156.1](CP027156.1)   127062--128305              29                   20                   186                     IncHI1B, IncFIB                 *aac(6′)-Ib, aac(6′)-Ib-cr*
  28           pKPN-edaa                                          *Kp*             [CP026398.1](CP026398.1)   7401--8525                  29                   18                   249                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*OXA--*1~, *bla*~*DHA--*1~, *aph(3′′)-Ib, aph(6)-Id, aac(6′)-Ib-cr, qnrB4, sul1*
  29           pKPN-bbef                                          *Kp*             [CP026172.1](CP026172.1)   227283--228407              29                   18                   244                     IncHI1B, IncFIB                 None
  30           pKpvST101_5                                        *Kp*             [CP031372.1](CP031372.1)   144828--145262              25                   10                   210                     IncHI1B, IncFIB                 None
  31           pKpn23412-362                                      *Kp*             [CP011314.1](CP011314.1)   141865--142618              23                   12                   362                     IncHI1B, IncFIB                 *bla*~*OXA*--1~, *bla*~*CTX--M--*15~, *bla*~*TEM--*1*B*~, *bla*~*OXA--*1~, *aac(3)-IIa, aph(3′′)-Ib, aph(6)-Id, aac(6′)-Ib-cr, sul2, dfr1*
  32           p1502320-3                                         *Kp*             [CP031580.1](CP031580.1)   7608--8781                  29                   19                   87                      ND                              None
  33           pKP3301 DNA                                        *Kp*             [AP018748.1](AP018748.1)   3677--4373                  29                   11                   296                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*CTX--M--*15~, *bla*~*TEM--*1*A*~, *bla*~*OXA--*1~, *aph(3′)-VI, armA, aadA2, aac(6′)-Ib, aac(6′)-Ib-cr*
  34           SKGH01 plasmid unnamed 1                           *Kp*             [CP015501.1](CP015501.1)   7545--7875                  29                   15                   281                     IncHI1B, IncFIB                 None
  35           Plasmid_A\_Kpneumoniae_MS6671                      *Kp*             [LN824134.1](LN824134.1)   16764--17823                29                   17                   280                     IncHI1B, IncFIB                 None
  36           pKJNM8C2.1                                         *Kp*             [CP030858.1](CP030858.1)   10639--11155                30                   8                    304                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*CTX--M--*15~, *bla*~*OXA--*1~, *armA, aadA2, aac(6′)-Ib-cr, qnrB1, sul1, dfrA12*
  37           pPMK1-NDM                                          *Kp*             [CP008933.1](CP008933.1)   10628--11144                30                   8                    304                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*CTX--M--*15~, *bla*~*OXA--*1~, *armA, aadA2, aac(6′)-Ib-cr, qnrB1, sul1, dfrA12*
  38           pFB2.1                                             *Pg*             [CP014776.1](CP014776.1)   56849--57852                29                   16                   242                     IncFIB                          None
  39           pE20-HI3                                           *Kp*             [MG288682.1](MG288682.1)   27978--29043                29                   17                   240                     IncFIB                          *bla*~*OXA--*1~, *armA, aac(6′)-Ib-cr, sul1*
  40           pEC422_1                                           *Ec*             [CP018961.1](CP018961.1)   276922--277868              29                   15                   290                     IncHI1B, IncFIB                 *bla*~*CTX--M--*2~, *bla*~*TEM--*1*B*~, *bla*~*OXA--*1~, *aac(6′)-Ib-cr, aac(3)-IIa, sul1*
  41           pNDM-TJ03                                          *Kp*             [MG845201.1](MG845201.1)   130378--131435              29                   17                   280                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*OXA--*1~, *bla*~*SHV--*12~, *bla*~*DHA--*1~, *aph(3′′)-Ib, aph(6)-Id, aac(6′)-Ib-cr, qnrB4, sul1*
  42           pNDM-TJ11                                          *Ko*             [MG845200.1](MG845200.1)   130294--131351              29                   17                   275                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*OXA--*1~, *bla*~*DHA--*1~, *aph(3′′)-Ib, aph(6)-Id, aac(6′)-Ib-cr, qnrB4, sul1*
  43           pENVA                                              *Kp*             [HG918041.1](HG918041.1)   99454--100629               23                   19                   254                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*OXA--*1~, *bla*~*SHV--*12~, *bla*~*DHA--*1~, *aph(3′′)-Ib, aph(6)-Id, aac(6′)-Ib-cr, qnrB4, sul1*
  44           pKP64477b                                          *Kp*             [MF150122.1](MF150122.1)   84064--85428                29                   22                   205                     IncHI1B, IncFIB                 None
  45           *Raoultella ornithinolytica* strain 18 plasmid 1   *Ro*             [CP012556.1](CP012556.1)   115417--115897              29                   7                    216                     ND                              None
  46           pKPN1481-1                                         *Kv*             [CP020848.1](CP020848.1)   325794--326308              29                   8                    347                     IncHI1B, IncFIB                 *bla*~*NDM--*1~, *bla*~*CTX--M--*15~, *bla*~*OXA--*1~, *bla*~*TEM--*1*A*~, *bla*~*OXA--*9~, *aac(6′)-Ib, aac(6′)-Ib-cr, aadA1, qnrB1*
  47           pK66-45-1                                          *Kp*             [CP020902.1](CP020902.1)   None                        0                    0                    338                     IncFIB, IncFII, IncHI1B, IncR   *bla*~*NDM--*1~, *bla*~*CTX--M--*15~, *armA, aadA2, aph(3′)-VI, qnrS1, sul1, dfrA12*

a

Kp, K. pneumoniae; Pg, Pluralibacter gergoviae; Ec, E. coli; Ko, Klebsiella oxytoca; Ro, Raoultella ornithinolytica; Kv, Klebsiella variicola.

b

ND, not detected.

c

aac(6′)-Ib

also commonly annotated as

aacA4; aph(3′′)-Ib, aph(6)-Id

also commonly annotated as

strA, strB.

![Schematic representation of type IV-like CRISPR-Cas system in plasmids found in Enterobacteriaceae. Putative genes are identified. CRISPR associated genes *(Cas)* are shown in red, *DinG helicase* in blue, unknown/hypothetical genes in yellow. Black rectangle indicates a putative leader sequence; blue diamonds are for CRISPR-repeats and colored rectangles are for acquired spacers, together consisted CRISPR-array.](fmicb-10-02934-g001){#F1}

CRISPR-Cas System in Other Enterobacteriaceae Plasmids {#S3.SS2}
------------------------------------------------------

A BLAST search identified identical CRISPR-Cas systems in 10 other plasmids in GenBank, in addition to the 37 plasmids identified in *K. pneumoniae* ([Table 1](#T1){ref-type="table"}). Five of these 10 plasmids were from *K. pneumoniae* and 1 each from *E. coli*, *K. oxytoca*, *Pluralibacter gergoviae, K. variicola*, and *Raoultella ornithinolytica*. One of the plasmids from *K. pneumoniae* has a *cas* locus without any CRISPR-array identified. No match was found in chromosomal sequences on GenBank.

Characterization of CRISPR-Positive Plasmids {#S3.SS3}
--------------------------------------------

A total of 47 type IV CRISPR-positive plasmids were analyzed. All but two are very large (\>200 kb) and the largest is 430 kb ([Table 1](#T1){ref-type="table"}). Almost all had an IncFIB replicon identified by PlasmidFinder except for two in which no replicon match was identified. Most plasmids (36/47) also have an IncHI1B replicon ([Table 1](#T1){ref-type="table"}). Interestingly, although most of the plasmids (44/47) were found in *Klebsiella* species, only one plasmid has the characteristic *Klebsiella* type IncFIB~*K*~ replicon ([@B12]). The %GC content of almost all CRISPR-negative plasmids is \> 50% and lower (∼44--46%) in CRISPR-positive plasmids ([Supplementary Table S1](#DS1){ref-type="supplementary-material"}). The only CRISPR-positive plasmid with an IncFIB~*K*~ replicon had a GC content of ∼52%, similar to other CRISPR-negative plasmids of *K. pneumoniae*.

ResFinder identified multiple antibiotic resistance genes including *bla*~*CTX--M*~, *bla*~*NDM*~, *bla*~*OXA*~, *armA* and *qnr* genes, associated with resistance to β-lactam, carbapenem, aminoglycoside and quinolone antibiotics, in almost half the plasmids (24/47; [Table 1](#T1){ref-type="table"}).

Analysis of Spacers From Plasmid CRISPRs {#S3.SS4}
----------------------------------------

A total of 623 spacers from 46 CRISPR-positive plasmids were analyzed by BLASTn search, identifying 67 unique spacer sequences that made up the total pool of 623, including some repetition or reversed orientation of the same sequence, along with loss or gain of a few nucleotides ([Figure 2](#F2){ref-type="fig"} and [Supplementary Table S2](#DS1){ref-type="supplementary-material"}). Spacer numbers varies without any relationship with plasmid size or the presence or absence of antibiotic resistance genes ([Table 1](#T1){ref-type="table"}). Five unique spacers (SP11, 36, 43, 55, 57) were found specific for plasmid sequences other than the match with CRISPR-array region and one of them (SP11) appears to match with the *traL* gene of 457 different CRISPR-negative plasmid sequences and another one (SP43) hits the *traN* gene of 260 different CRISPR-negative plasmid sequences in GenBank, mostly (\>98%) from *K. pneumoniae* ([Table 2](#T2){ref-type="table"} and [Supplementary Table S2](#DS1){ref-type="supplementary-material"}). Both spacers are found in the CRISPR-array of 17 of the 46 CRISPR-positive plasmids we examined ([Table 2](#T2){ref-type="table"}). Spacers SP36, SP55, and SP57 have identity with plasmid *transposases*, *transcriptional regulator* and *traH* gene, respectively. Genes, *traL, traN*, and *traH* play an important role in plasmid transfer and are highly conserved among plasmids. Five unique spacers (SP8, 20, 42, 62, 63) were also found to match *K. pneumoniae* chromosomes but not those of their current host bacteria ([Table 2](#T2){ref-type="table"} and [Supplementary Table S2](#DS1){ref-type="supplementary-material"}). Two of them occurred in 17 of the 46 plasmids, targeting *DUF1367 family protein* and *hypothetical protein* genes for 111 and 139 *K. pneumoniae* chromosomes, respectively. Another spacer, that occurred in one plasmid only, appears to recognize a *hypothetical protein* gene from 3 of the *K. pneumoniae* chromosomes ([Table 2](#T2){ref-type="table"}). Many spacers (18/67) did not have any match in GenBank ([Supplementary Table S2](#DS1){ref-type="supplementary-material"}).

![A spacer map for the distribution of spacers in plasmid CRISPRs. Spacers are represented in box without repeats. Identical spacers are represented by same number and color or pattern. Spacers found in reverse orientation in the plasmid CRISPR are shown by reverse arrow at the bottom of the spacer. Exactly same spacers and their orientation are shared by a number of plasmids and are mentioned below in the brackets, and spacers from one of them were represented in the figure. Those plasmids are (^∗^CP030878.1, CP020068.1, CP0016921.1, CP028929.1, CP024507.1, CP020854.1), (^∗∗^CP018708.1, CP018702.1, CP018696.1, CP018720.1), (^∗∗∗^CP018687.1, CP018714.1, CP017986.1), (\#CP022612.1, CP012754.1, CP006799.1), (\#\#MG845201.1, MG845200.1) and (\#\#\#CP030858.1, CP008933.1) and marked with asterisk or hashtag were the representative from each group showed in the figure. The unique spacer sequences and their match with protospacers will be found in [Supplementary Table S2](#DS1){ref-type="supplementary-material"}.](fmicb-10-02934-g002){#F2}

###### 

Spacers from plasmid mediated CRISPR specific to plasmids and *K. pneumoniae* chromosomes.

  **Spacer**                                                   **Hits to**                    **Target gene**                  **No. of occurrence**
  ------------------------------------------------------------ ------------------------------ -------------------------------- -----------------------
  CCGAGATTGAGTAAAGCAAAGTAACGGCGGTG                             111 *Kp* strains chromosome    *DUF1367* family protein         17
  TTCCGGACTCCTGTTTCCGGCAGTGGATTAAA                             457 CRISPR-negative plasmids   *traL*                           17
  CCGAGCTACCGATTTACCAGGAGAGCGCTCGC                             139 *Kp* strains Chromosome    *hp*                             17
  CCGGTTCGGATTTTGCGAAACAGGTGCAGGGC                             260 CRISPR-negative plasmids   *traN*                           17
  TTGGCGACCACCAGCGTTTTAGTGCAGGGAAC                             3 *Kp* strains chromosome      *hp*                             1
  AAGTTATTCATGTCGCCATTCACGTCGGCGGCGTATTT                       62 CRISPR-negative plasmids    *traH*                           1
  TTCTCTCCGCCGGGCAGTGTGATGCCGGAGGGGTATTC                       7 CRISPR-negative plasmids     *transcriptional regulator*      1
  ATTTACAAATGAAGATTTTTCCCCATTGGTAA                             48 CRISPR-negative plasmids    IS200/IS605 family transposase   10
  TTCCCTGCACTAAGACGCTGGTGGTCGCCAC                              17 Kp strains chromosome       *hp*                             9
  AGTTTGTATGAAAGCCTCATGTTTTGCACCTGTGCCGG TGCATATCATCCTCAGAGC   6 *Klebsiella* chromosome      *hp*                             1

hp

, hypothetical protein.

Analysis of CRISPR-Cas System in *K. pneumoniae* Chromosomes {#S3.SS5}
------------------------------------------------------------

A total of 217 *K. pneumoniae* complete chromosomal sequences were extracted from GenBank (June 2019) and we identified that 81 of these (37%) carried CRISPR-Cas system on the chromosome. Of these 81, 45 were I-E and 36 were I-E^∗^ type ([Supplementary Table S3](#DS1){ref-type="supplementary-material"}), consistent with previous reports ([@B31]; [@B40]; [@B21]).

Relationship Between the Presence of Chromosomal CRISPR and Plasmid in *K. pneumoniae* Bacteria {#S3.SS6}
-----------------------------------------------------------------------------------------------

We also gathered information about the presence of plasmids in those 217 *K. pneumoniae* isolates from GenBank. Most bacteria (185 of 217, 85%) carried plasmids, from 1 to 10 in number ([Figure 3A](#F3){ref-type="fig"} and [Supplementary Table S3](#DS1){ref-type="supplementary-material"}) and 37% of these 217 had the putative CRISPR-Cas system. We found that the occurrence of chromosomal CRISPR is more in plasmid-free than plasmid-carrying strains (43 vs. 35%) ([Figure 3B](#F3){ref-type="fig"}), a relationship that has been noted before ([@B21]). We found that bacteria with chromosomal type I-E CRISPR had more plasmids (from 1 to 7 in number, most with 4--5 plasmids) whereas bacteria with chromosomal type I-E^∗^ CRISPR had less plasmids (from 0 to 4 in number, mostly only 1 or 2 plasmids or none) ([Supplementary Table S3](#DS1){ref-type="supplementary-material"}).

![Distribution of chromosomal CRISPR-Cas system and plasmids in *K. pneumoniae* strains **(A)**. Distribution of CRISPR-Cas in plasmid-positive and -negative strains **(B)**.](fmicb-10-02934-g003){#F3}

Analysis of Spacers From *K. pneumoniae* Chromosomal CRISPRs {#S3.SS7}
------------------------------------------------------------

A total of 2,464 spacers were extracted from chromosomal CRISPR-positive strains. A BLASTn search with these spacers matched *K. pneumoniae* chromosomal sequences as well as different mobile elements including bacteriophages and plasmids. We identified 18 unique spacers matched sequences on plasmids ([Table 3](#T3){ref-type="table"}). Interestingly, 5 of these 18 spacers were from plasmid conjugative transfer region genes (*traH, traG, traT, traN, traF*) in several hundred different plasmid sequences in GenBank. Spacers matching *traH* and *traG* gene sequences from 413 and 401 different plasmids respectively were identified. One spacer matched the plasmid segregation gene *parM*, one matched the ubiquitous toxin antitoxin system gene *hok-sok* ([Table 3](#T3){ref-type="table"}), one matched the *SAM-methyl transferase* gene and another matched DNA sequence in a hypothetical gene located immediate upstream of *SAM-methyltransferase* on the plasmid. Three spacers matched different regions in the *DUF3560 domain-containing protein* gene, which was found in turn on ∼1,000 plasmids in GenBank. One spacer matched *ydeA*, two matched a hypothetical protein and other three in intergenic regions of plasmid sequences; one spacer matched an intergenic region with identity to 524 different plasmids ([Table 3](#T3){ref-type="table"}) which, in a few cases, was present in multiple times in a single plasmid sequence.

###### 

Plasmid specific spacers in *K. pneumoniae* chromosomal CRISPR.

  **Spacers**                        **Target gene on plasmid^a^**                                                 **No. of plasmid matched**   **No. of occurrence in chromosome**
  ---------------------------------- ----------------------------------------------------------------------------- ---------------------------- -------------------------------------
  TACTGCAGCAGGATGTCGTAGCCGATATAGTC   Conjugal transfer protein *traH*                                              413                          1
  ATAGAAAAGATGTGTATCGCCATCTCGGTACT   Conjugal transfer protein *traG*                                              401                          1
  TTTGGTATTTGTGCTGATTACCCGTTTCAGTA   Conjugal transfer protein *traT*                                              126                          1
  GAAATAACCGTCTTCATTTCCACCCTCCCTCA   Type-F conjugative transfer system mating-pair stabilization protein *traN*   90                           1
  GATACAGAATGGCTTCGTACAGCGACCGTTTG   Type-F conjugative transfer system pilin assembly protein *traF*              20                           1
  GTGGTTTGTTACCGTGTTGTGTGGCAAAAAGC   *hok-sok* toxin-antitoxin system                                              152                          5
  CGTGACCATTGATACGCCAATATCAGGATTAC   Plasmid segregation protein *parM*                                            13                           1
  CCGCCGTTTAATCGCGGTGATGATATCCGGCA   *SAM-dependent methyltransferase*                                             209                          7
  GTCTTCCCTGTTTGCTGCCTGCTGTCTGTCTG   *hp*, immediate upstream of *SAM-dependent methyltransferase*                 405                          29
  GGGGACCTGCTGAACCTGCCCCCTGGTATTAA   *DUF3560* domain-containing protein                                           214                          24
  CGATAACCGGGCGTTTCGACTGAACTCACCTC   *DUF3560* domain-containing protein                                           351                          24
  TTGATACGGCGGTAACGCACATCCGGACGCTC   *DUF3560* domain-containing protein                                           425                          1
  CCGGCATCCGTCAGCTCGACGGCCAGCTGCAG   *ydeA* protein                                                                19                           24
  TGATTGACGCGAAGCTGCGTTATCCCAACACC   *hp*                                                                          19                           1
  GCAGCATGAACGTTTCCCACTCGCCGTTCTCA   *hp*                                                                          93                           1
  GAGCAGGCACCCGCCGCAACGACGAAGAGCGC   Intergenic region/*hp*, (2--4 hits in same plasmid)                           524                          19
  GAACGGAGGAATATAAGAACAAAAGCCCGCAG   Intergenic region                                                             145                          1
  TCGTCTGAGTTCCGGCTTACGCCGTGCCGACA   Intergenic region                                                             178                          5

a

hp

for hypothetical protein.

Discussion {#S4}
==========

In this study we have identified a putative type IV CRISPR-Cas system in the plasmids of *K. pneumoniae*. To our knowledge, this is the first comprehensive report of type IV CRISPR-Cas system in plasmids of *K. pneumoniae*, specifically in antibiotic resistance plasmids.

Type IV CRISPR-Cas was previously identified in a mega-plasmid of *Aromatoleum aromaticum* species, an aromatic-degrading β-proteobacteria found in freshwater and soils. The CRISPR-positive plasmids we describe are also very large (200--430 kb; [Table 1](#T1){ref-type="table"}). Like the previously reported type IV CRISPR-Cas system ([@B24]; [@B9]; [@B34]) homologs of *cas* region genes *csf2*, *csf3*, *DinG helicase (csf4)*, *cas6* (*csf5*) were present, the organization of the *cas* genes was very similar and the adaptation genes *cas1* and *cas3* were absent, all typical of the previously reported type IV CRISPR-Cas. The large subunit *csf1* gene thought to be the signature gene for type IV system was absent in the CRISPR-Cas system reported here, but two additional *cas* genes (*csx3* and *cas10* homologs) and two genes of unknown functions were identified in the *cas* gene locus, any of which may compensate for the absent *csf1*. The Cas1 protein of type IV CRISPR-Cas is a Zn-finger containing protein with a weak similarity to Zn-finger sequences of Cas10 and it has been suggested that Csf1 could be a highly divergent, inactivated and N-terminally truncated Cas10-like polymerase derivative ([@B22]). The presence of *DinG helicase (csf4)*, only previously reported in type IV-A CRISPR-Cas ([@B20]; [@B25]; [@B34]), further supports the designation of these plasmid systems as type IV-A CRISPR-Cas.

A preliminary study identified putative type IV CRISPR-Cas system in the IncH1B/IncFIB plasmids of Enterobacteriaceae ([@B9]). In the present study most (45 of 47) of these very large CRISPR-carrying plasmids had an IncFIB replicon identified and most had an additional IncHI1B replicon. We identified only one of the IncF replicons that are thought to be typical (i.e., IncFIB~*K*~) of *K. pneumoniae* ([@B12]; [@B43]). This suggests that CRISPR-positive plasmids might have originated from some other species in Enterobacteriaceae and transferred into *K. pneumoniae*. Analysis of %GC content shows that almost all CRISPR-positive plasmids have lower %GC (44--46%) than CRISPR-negative plasmids (∼50% or greater); we identified only one IncFIB~*k*~ plasmid with CRISPR (pKPM501) and this had a 'normal' %GC of \> 51%.

Plasmids have their own genetic modules that they can utilize to exist stably in certain bacterial host by competing with other plasmids. Plasmid incompatibility is one of the such mechanism by which two plasmids with similar or related replication genes cannot co-exist in the same cell. By interfering with host replication system only one plasmid of similar type can be efficiently replicate and segregate to daughter cell and others lost form the system ([@B29]; [@B1]). Acquiring antibiotic resistance genes also give plasmids the advantage to maintain over sensitive plasmids at antibiotic selection pressure ([@B6]). Plasmid mediated toxin-antitoxin (TA) module also provide another alternative to displace incompatible plasmid by toxin mediated killing of plasmid free cells ([@B16]; [@B44]). For example, if a cell carries two incompatible plasmids and one plasmid encodes a TA system, then after segregation of these incompatible plasmids, only plasmid carrying TA system will be maintained into daughter cells and cells carrying the other plasmid are eliminated from the population. Similar to those systems, it was suggested that plasmid mediated type IV CRISPR-Cas system may involve in the competition between plasmids by acquiring spacers specifically targeting different plasmids ([@B34]). Chromosomal CRISPR are known to acquire spacers against different MGEs ([@B37]) and many plasmid-borne CRISPR spacers we found were also directed against other plasmids, including three unique spacers targeting 100% identical sequences (the common and highly conserved *traN, traH*, and *traL* of conjugative plasmids) in more than 700 other plasmids in GenBank. Large potentially expensive plasmids such as these CRISPR-positive plasmids may need this competitive edge and may reduce the overall plasmid burden in their host bacteria. Plasmid CRISPR spacers targeting heterologous *K. pneumoniae* chromosomes may also have a role in determining the epidemiology of plasmids in this species.

Acquisition of a new plasmid produces burden to the host by reducing growth rate and lessened competitiveness of plasmid-bearing hosts under conditions that do not select for plasmid genes ([@B38]). Although this fitness-cost can be mitigated over time through compensatory evolutions, however, the initial cost associated with plasmid carriage is one of the main barrier in the acquisition, maintenance and transfer of new plasmids ([@B38]; [@B8]). Multiple plasmids impose more fitness-cost related to single plasmid. Acquisition of plasmid mediated CRISPR spacers targeting other plasmids and host chromosome may provide advantage in the formation of plasmid co-integrate with other plasmids or integrated into the host chromosome by homologous recombination that might facilitate the stability and compatibility of the plasmids. CRISPR-Cas defense system not only identified in plasmids but also distributed in other MGEs including bacteriophages, T7-transposable elements and integrative conjugative elements (ICEs) ([@B10]; [@B19]). The recruitment of CRISPR-Cas defense system by different MGEs may contribute to the evolution of both MGEs and defense systems.

Several previous studies identified and analyzed chromosomal CRISPR-Cas systems in *K. pneumoniae* by analyzing 52 ([@B31]), 68 ([@B40]) and 97 ([@B21]) complete and draft genome sequences. Here, we analyzed 217 complete *K. pneumoniae* chromosomes available in GenBank for the distribution of CRISPR-Cas systems, their types, acquired spacers and relationship between presence and absence of CRISPR and plasmids. Consistent with previous studies, we found type I-E and type I-E^∗^ CRISPRs distributed in *K. pneumoniae* chromosomes. We found that chromosomal CRISPR-negative strains had more plasmids ([Figure 3](#F3){ref-type="fig"} and [Supplementary Table S3](#DS1){ref-type="supplementary-material"}) and that *K. pneumoniae* with type I-E^∗^ chromosomal CRISPR appeared to have less plasmids than those with type I-E.

Spacer sequences from chromosomal CRISPR matched different MGEs including plasmids. A total of 18 unique spacers were acquired from plasmids and many from conjugative transfer region genes, plasmid partition (*parM*) and stability genes (*hok-sok*). Acquired plasmid-specific spacers in *K. pneumoniae* chromosomal CRISPR may provide immunity against plasmids and, it has been suggested, promote or select for mobilization of important plasmid-borne antibiotic resistance genes such as *bla*~*CTX--M*~ and *bla*~*KPC*~ onto the chromosome ([@B18]). Similar phenomena have been directly observed for *Streptococcus thermophilus* CRISPR-Cas systems ([@B13]).

Type IV CRISPR-Cas systems on plasmids lack genes for target cleavage enzymes (*cas3* or *cas10*) ([@B24]) but we have identified a putative *cas10-like* gene in these plasmid CRISPR-Cas system in Enterobacteriaceae. They also lack key adaptation modules (*cas1* and *cas2*) but RNA processing and effector complex formation has been experimentally demonstrated for these systems in *Aromatoleum aromaticum*, in which a chromosomal type I-C CRISPR is also present ([@B32]). Importantly, we also noted that type IV CRISPR-Cas system-positive plasmids were found only in bacteria with chromosomal type I-E or I-E^∗^ CRISPR-Cas, suggesting cross-talk between plasmid and chromosomal CRISPR which may compensate for the lack of adaptation and target cleavage functions encoded from plasmid mediated CRISPR.

Chromosomal CRISPR-Cas systems clearly protect some bacteria from horizontally acquired mobile elements ([@B33]; [@B36]). Multi-drug resistant *Enterococcus* lacking CRISPR-Cas ([@B33]) more readily acquire new genes and adapt to new antibiotics ([@B36]). *Vibrio cholerae* that acquired phage-inducible chromosomal islands (PICI) as a defense against bacteriophages ([@B30]; [@B39]) now must contend with bacteriophages that have acquired CRISPR-Cas with spacers directed against chromosomal PICI to inactivate that very defense system ([@B27]). We describe here a novel type IV CRISPR-Cas that is evidently circulating in Enterobacteriaceae plasmids, predominantly within *K. pneumoniae*, and appears to have a complementary relationship with chromosomal Type I-E/I-E^∗^ CRISPRs. Plasmid CRISPR-Cas directed against other plasmids (and some *K. pneumoniae* chromosomes) provide another level of incompatibility in plasmid communities. Both plasmid and chromosomal CRISPR-Cas are evidently important determinants of the epidemiology of large antibiotic resistance plasmids in *K. pneumoniae*.
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